Vanguard Capital Management
GYRE icon

Vanguard Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Vanguard Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.78M Sell
876,927
-107,277
-11% -$731K ﹤0.01% 3067
2026
Q1 		$6.86M Buy
+984,204
New +$7.64M ﹤0.01% 2928

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management's GYRE Position: Q2 2026 in Review

Vanguard Capital Management reduced its Gyre Therapeutics (GYRE) stake by 11% in Q2 2026, selling an estimated $731K and leaving 876,927 shares worth $5.78M. The position accounts for ﹤0.01% of the portfolio, ranked #3067.

Vanguard Capital Management first reported a position in GYRE in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.86M in Q1 2026. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Vanguard Capital Management held 876,927 shares of Gyre Therapeutics worth $5.78M as of Q2 2026.
  • Vanguard Capital Management sold 107,277 Gyre Therapeutics shares in Q2 2026, an estimated $731K.
  • Gyre Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3067 holding.
  • Vanguard Capital Management first reported a position in Gyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Gyre Therapeutics position peaked at $6.86M in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.